IMR Press / RCM / Volume 22 / Issue 1 / DOI: 10.31083/j.rcm.2021.01.286
Open Access Case Report
Sildenafil-triggered multi-culprit ST-segment elevation myocardial infarction: a case report
Show Less
1 Division of Hemato-Oncology, Department of Internal Medicine, Seoul Paik Hospital, 04551 Seoul, Republic of Korea
2 Inje University, College of Medicine, 47392 Busan, Republic of Korea
3 Division of Cardiology, Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University, 01830 Seoul, Republic of Korea
Rev. Cardiovasc. Med. 2021, 22(1), 185–189;
Submitted: 18 December 2020 | Revised: 4 February 2021 | Accepted: 6 February 2021 | Published: 30 March 2021

Sildenafil citrate and its generic forms are widely used to treat erectile dysfunction worldwide. Sildenafil citrate associated myocardial infarction is rarely reported in patients with no previous coronary artery disease. Herein, we present a case of a 40-year-old man with no cardiovascular risk factors other than heavy smoking and heavy drinking with no known previous ischemic symptoms, who had an ST-segment elevation myocardial infarction after receiving sildenafil citrate. From this case report, we emphasize that as sildenafil is increasingly being used as a recreational drug as it is widely available without a physician’s prescription, physicians should be aware that it may reveal the underlying cardiovascular problem. Thus, physicians must also consider the underlying medical conditions when prescribing sildenafil.

ST-segment elevation myocardial infarction
Fig. 1.
Back to top